New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 1, 2014
07:09 EDTSHPGShire reports Q1 EPS $2.36, consensus $2.22
Reports Q1 revenue $1.35B, consensus $1.38B. Shire said, "We'll shortly be meeting with the FDA to determine our next steps with lifitegrast. We continue to advance our intrathecal enzyme replacement therapy program for rare pediatric CNS diseases. In addition, the ViroPharma acquisition brought us the Phase 2 program for maribavir, an investigational treatment under development for cytomegalovirus infection in transplant patients, as well as several potential new uses for CINRYZE. And, our acquisition of Fibrotech adds FT011, a small molecule targeting an innovative, novel mechanism of action, currently in a Phase 1B study in patients with renal impairment, and a Phase 2 study in patients with FSGS, a rare kidney disease, is planned."
News For SHPG From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
August 25, 2015
16:43 EDTSHPGOn The Fly: Top stock stories for Tuesday
Subscribe for More Information
09:03 EDTSHPGAcorda has major overhang removed by IPR denials, says Leerink
Subscribe for More Information
07:06 EDTSHPGShire reaches CINRYZE agreement with Sanquin Blood Supply
Subscribe for More Information
August 24, 2015
18:55 EDTSHPGOn The Fly: After Hours Movers
Subscribe for More Information
18:52 EDTSHPGJazz, Celgene, Shire up after USPTO rejects Acorda patent challenge
Subscribe for More Information
August 21, 2015
09:38 EDTSHPGUBS global healthcare analysts hold an analyst/industry conference call
Subscribe for More Information
August 17, 2015
06:55 EDTSHPGBaxalta initiated with an Outperform at William Blair
Subscribe for More Information
06:48 EDTSHPGShire to raise Baxalta offer if given access to company's books, Telegraph says
Subscribe for More Information
August 16, 2015
15:03 EDTSHPGShire must raise bid to $35B to interest Baxalta, Sunday Times says
Shire (SHPG) will have to increase its bid for Baxalta (BXLT) by about $5B to $35B in order to entice the company's board, reports the Sunday Times, citing people working on the deal. Even a $35B deal would only be a starting point, cautioned the sources. Reference Link
August 14, 2015
17:08 EDTSHPGPaulson & Co gives quarterly update on stakes
Subscribe for More Information
07:15 EDTSHPGShire eyes more details of Baxalta sales outlook, Bloomberg reports
Subscribe for More Information
August 13, 2015
10:02 EDTSHPGMajor Shire holders comfortable with $50 per share Baxalta bid, Reuters says
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.
I agree to the theflyonthewall.com disclaimer & terms of use